Wedbush Has Lowered Expectations for Avalo Therapeutics (NASDAQ:AVTX) Stock Price

Avalo Therapeutics (NASDAQ:AVTX) had its price target lowered by stock analysts at Wedbush from $40.00 to $34.00 in a report released on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s price target indicates a potential upside of 71.28% from the company’s current price.

AVTX has been the subject of a number of other research reports. BTIG Research boosted their price objective on Avalo Therapeutics from $40.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Wednesday, April 8th. Piper Sandler reaffirmed an “overweight” rating and issued a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a report on Monday. HC Wainwright reduced their price target on shares of Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Wall Street Zen upgraded shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $49.00.

Avalo Therapeutics Stock Performance

Shares of AVTX stock opened at $19.85 on Thursday. The stock’s 50-day moving average is $15.84 and its two-hundred day moving average is $16.44. Avalo Therapeutics has a 1 year low of $3.39 and a 1 year high of $24.27. The firm has a market cap of $582.20 million, a price-to-earnings ratio of -3.46 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last posted its earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. As a group, research analysts predict that Avalo Therapeutics will post -3.1 EPS for the current year.

Insider Activity

In related news, insider Paul Varki sold 75,063 shares of Avalo Therapeutics stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the completion of the transaction, the insider directly owned 3,634 shares of the company’s stock, valued at approximately $73,297.78. The trade was a 95.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of the business’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $18.01, for a total value of $71,499.70. Following the sale, the insider owned 3,622 shares in the company, valued at approximately $65,232.22. The trade was a 52.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 138,078 shares of company stock worth $2,501,346. Company insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its stake in Avalo Therapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after acquiring an additional 2,648 shares during the last quarter. Nantahala Capital Management LLC raised its position in Avalo Therapeutics by 10.6% during the second quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock worth $4,965,000 after acquiring an additional 95,000 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Avalo Therapeutics by 7,066.8% in the second quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock valued at $2,029,000 after purchasing an additional 400,898 shares in the last quarter. Boothbay Fund Management LLC purchased a new stake in shares of Avalo Therapeutics in the second quarter valued at about $56,000. Finally, Aberdeen Group plc acquired a new stake in shares of Avalo Therapeutics in the third quarter valued at approximately $925,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.